Systemic amyloidosis manifestation in a patient with psoriatic arthritis

Abstract

Systemic amyloidosis secondary to psoriatic arthritis is rare, and published data are based mainly on case reports and are associated with increased mortality. This is the report of a patient with long-term psoriatic arthritis and chronic sialadenitis, who showed an inadequate response to therapy. The diagnosis of secondary amyloidosis was attained through biopsies of genital skin lesions. Although very rare, it is important that dermatologists and general practitioners consider the possibility of amyloidosis in patients with chronic inflammatory diseases, since an early intervention can be implemented, and thus, the prognosis of this condition can be improved.

Trends in amyloidosis in spondyloarthritis: results from the Spanish National Inpatient Registry over a 17-year period (1999–2015)—TREND-EspA study

“…Third, the type of SpA most strongly associated with amyloidosis was SpA-IBD (AOR 22.9; 95% CI 16.6 to 31.7). Fourth, while it is generally perceived that the risk of amyloidosis is lower in patients with PsA than those with AS, 18 in our study, the strength of association was similar for these two types.…”

“… 8 9 While both the incidence and the prevalence of AA amyloidosis are falling in Western countries, presumably reflecting advances in the treatment of underlying disorders, 5 10–14 few studies have exclusively focused on this condition in patients with SpA, 15–17 and few have compared the incidence of AA amyloidosis in patients with different types of SpA. 18 …”

“…9 While both the incidence and the prevalence of AA amyloidosis are falling in Western countries, presumably reflecting advances in the treatment of underlying disorders, 5 10-14 few studies have exclusively focused on this condition in patients with SpA, [15][16][17] and few have compared the incidence of AA amyloidosis in patients with different types of SpA. 18 The treatment of SpA has significantly improved over the last 20 years, due to early diagnosis and the introduction of biological therapies. Given all these, it seems reasonable to venture to suggest that the new treatment paradigm for SpA may have a positive impact on trends in the incidence rate ratios (IRRs) of amyloidosis in patients with SpA.…”